Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
YCBD Catalyst Timeline
Dated clinical, regulatory and corporate events for cbdMD, Inc.
Past FDA Catalysts and PDUFA Decisions
How YCBD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
cbdMD, Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every YCBD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Crosnoe Clark R.10% Owner | Sell | -461,725 361,400 held | $2.31 | 12/17/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in YCBD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in YCBD for Q3 2026. | ||||
Ownership Trends
YCBD Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How YCBD ranks across every disease it competes in
YCBD News
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
cbdMD supports the Bipartisan Hemp Guardrails Act, introduced by Senators Sheehy and Klobuchar, to establish federal standards for hemp products. The legislation averts a December 11 ban that would remove lawful items from the market. cbdMD CEO Ronan Kennedy stated the bill protects consumers while preserving 350,000 American jobs. The company also highlighted its diversified portfolio, including Twinlab, to mitigate regulatory risks.
Read more →cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
cbdMD has successfully acquired the operating assets of Twinlab, including its well-known brands like Reserveage and Metabolife. This acquisition aims to diversify cbdMD's offerings beyond hemp products and enhance its market presence. CEO Ronan Kennedy emphasized the significance of this deal for the company's growth and innovation strategy.
Read more →Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation
Reserveage has launched Longev+, a new supplement available exclusively at The Vitamin Shoppe. This product combines essential amino acids, HMB, creatine, and resveratrol to support muscle health and performance. The launch reflects consumer demand for simpler wellness routines and flavorful supplements. It also aligns with cbdMD's proposed acquisition of Twinlab brands.
Read more →cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness
cbdMD has signed a definitive agreement to acquire Twinlab Brands, which includes well-known names like Twinlab, Reserveage, and Metabolife. This acquisition is anticipated to boost cbdMD's revenue to around $30 million and diversify its product offerings beyond hemp-derived products. The deal is subject to court approval and aims to stabilize Twinlab's brands while enhancing cbdMD's market presence.
Read more →cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
cbdMD reported a 20% increase in revenue for Q3 2026, driven by strong wholesale sales and contributions from Bluebird Botanicals. The company is also seeing positive momentum with its Oasis beverage brand. However, one-time costs related to mergers and acquisitions have impacted profitability. The regulatory landscape is improving, providing a favorable outlook for future growth.
Read more →cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results
cbdMD, Inc. will host a conference call on August 13, 2026, at 4:20 p.m. ET to discuss its third quarter financial results for the period ending June 30, 2026. The call will provide insights into the company's business progress and financial performance. Interested parties can join via a dedicated phone line or through a webcast.
Read more →cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products
cbdMD, Inc. has welcomed a proposed Senate spending bill that aims to delay federal restrictions on hemp products, preserving access to full-spectrum CBD. The bill, released on August 2, is seen as a significant victory for the hemp industry. However, it still requires approval from the House and the President before becoming law.
Read more →cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access
cbdMD, Inc. has announced its support for the bipartisan Lawful Hemp Protection Act, which aims to create a federal regulatory framework for hemp-derived products. This legislation is crucial as the federal definition of hemp is set to narrow in November 2026, potentially removing many lawful CBD products from the market. The Act seeks to ensure consumer access while implementing safety standards and oversight.
Read more →cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina
cbdMD, Inc. has announced the launch of its Oasis line of hemp-derived beverages in South Carolina through a partnership with Mexcor. The rollout includes the new zero-proof Mixer, designed for cocktails, now available at various liquor retailers. This strategic move aims to increase brand visibility and accessibility for consumers in familiar shopping environments.
Read more →cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
cbdMD's Bluebird Botanicals has partnered with Denver Audubon to support bird conservation in Colorado. This collaboration emphasizes Bluebird's commitment to environmental values and responsible growth. As part of the initiative, Bluebird will contribute 1% of its product sales to support conservation and education efforts. The partnership aims to strengthen Bluebird's identity while promoting community engagement in wildlife stewardship.
Read more →cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
cbdMD has announced the completion of a self-affirmed GRAS determination, allowing for the safe daily consumption of up to 200 mg of its broad spectrum CBD products. This conclusion is based on years of rigorous safety research and peer-reviewed studies. The determination is expected to enhance consumer confidence and support the company's product positioning in the growing CBD market.
Read more →Oasis Launches Hemp-Derived Mixer
cbdMD, Inc. has launched Oasis Mixer, a new hemp-derived THC spirit that is translucent and oil-free, addressing consumer demand for cleaner beverage options. The product is available in Citrus and Unflavored varieties, each containing 10mg of THC per serving. Initial demand has exceeded supply, indicating strong market interest. Oasis Mixer is compliant with child-resistant packaging regulations in Texas.
Read more →cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
cbdMD, Inc. has welcomed the White House's call for fair treatment of hemp-derived products, urging Congress to revise federal regulations. The Administration's push aims to preserve access to full-spectrum CBD while ensuring consumer safety. cbdMD believes it is well-positioned in the evolving cannabinoid market, advocating for responsible regulation and quality products.
Read more →cbdMD Appoints Wade Brown Chief Marketing Officer
cbdMD, Inc. has appointed Wade Brown as Chief Marketing Officer to lead its multi-brand expansion. Brown, who joined the company in March 2025, has played a crucial role in stabilizing the brand portfolio and supporting the acquisition of Bluebird Botanicals. The company reported a 19% year-over-year revenue growth, indicating strong momentum in its core brands. Brown's extensive experience in consumer marketing is expected to drive cbdMD's next phase of growth.
Read more →cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
cbdMD, Inc. reported a 19% year-over-year revenue growth for Q2 2026, driven by its core business and the integration of Bluebird Botanicals. The company is positioned for continued growth with the activation of the Medicare BEI pathway for hemp-derived CBD products. Despite increased operational losses, cbdMD remains optimistic about future opportunities in the evolving regulatory landscape.
Read more →cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
cbdMD, Inc. will host a conference call on May 14, 2026, at 4:20 p.m. ET to discuss its second quarter financial results for the period ending March 31, 2026. The call will provide insights into the company's business progress and financial performance. Interested parties can join via a dedicated phone line or through a webcast.
Read more →cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
cbdMD launched a clinical healthcare channel to supply hemp-derived CBD to Medicare patients under new CMS guidance. The Substance Access Beneficiary Engagement Incentive allows participating organizations to furnish these products. The company cites unique OECD-standard toxicology and human clinical trial data as key differentiators for physician adoption.
Read more →cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026
cbdMD, Inc. reported a 12% sequential revenue growth for Q1 of fiscal 2026, reflecting stabilization in its core business. The company also announced the strategic acquisition of Bluebird Botanicals, which is expected to enhance its revenue and operational efficiencies. Despite these positives, net sales saw a slight decrease compared to the previous year.
Read more →cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results
cbdMD, Inc. will host a conference call on February 17, 2026, at 4:20 p.m. ET to discuss its first quarter financial results for the period ending December 31, 2025. The call aims to provide updates on the company's business progress and financial performance. Interested parties can join via phone or webcast.
Read more →cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum
cbdMD announced a distribution expansion for its Herbal Oasis THC-infused seltzer into Louisiana through a partnership with Morales Beverage Group. This move follows strong sales in Texas and aims to enhance the brand's presence in the Gulf South. The company expects to start shipping products by late February.
Read more →